<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213746</url>
  </required_header>
  <id_info>
    <org_study_id>2003/011/HP</org_study_id>
    <nct_id>NCT00213746</nct_id>
  </id_info>
  <brief_title>Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)</brief_title>
  <official_title>Prediction of Left Ventricular Function Changes Using Low Dose Dobutamine Gated SPECT in Patients Referred for Viability Assessment: The DOGS (DObutamine Gated Spect)Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Médecine Nucléaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viability assessment remains a clinical challenge in patient with coronary artery disease and&#xD;
      left ventricular dysfunction. Several imaging modalities are available for evaluating&#xD;
      myocardial viability, based either on perfusion or on contractile reserve analysis. Briefly,&#xD;
      perfusion analysis is highly sensitive and contractile reserve highly specific. A combined&#xD;
      analysis of both perfusion and contractile reserve has been proposed to improve the&#xD;
      diagnostic accuracy in patient referred for a revascularization procedure. However, the value&#xD;
      of this combined analysis has not been validated in unselected patients referred for&#xD;
      viability assessment.&#xD;
&#xD;
      The patients enrolled in the study will undergo a nitrate enhanced rest gated SPECT using a&#xD;
      Tc-99m labeled tracer (sestamibi or tetrofosmine) followed by a second gated SPECT acquired&#xD;
      during a low-dose dobutamine infusion (10 mcg/kg/mn). All patients will have a 6-month&#xD;
      clinical and imaging follow-up, including physical examination and a nitrate enhanced rest&#xD;
      gated SPECT using the same radiopharmaceutical. All treatments received during this 6-month&#xD;
      period will be recorded, including medical therapy and coronary revascularization&#xD;
      (angioplasty, stenting and CABG).&#xD;
&#xD;
      Finally, the value of baseline perfusion and contractile reserve analysis in predicting left&#xD;
      ventricular ejection fraction changes at 6-month follow-up will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date>December 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Heart Failure, Congestive</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Stunning</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists with patients with documented coronary artery disease and&#xD;
        left ventricular dysfunction (LVEF &lt; 50%)referred to aNuclear Medicine department for&#xD;
        myocardial viability assessment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented coronary artery disease&#xD;
&#xD;
          -  Left ventricular dysfunction (LVEF &lt; 50%)&#xD;
&#xD;
          -  Patients referred to the Nuclear Medicine department for myocardial viability&#xD;
             assessment&#xD;
&#xD;
          -  Sinus Rhythm&#xD;
&#xD;
          -  Acceptance of a 6-month follow-up&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent acute coronary syndrome (&lt; 21 days)&#xD;
&#xD;
          -  Atrial Fibrillation or significant arrhythmias&#xD;
&#xD;
          -  Implanted pacemaker&#xD;
&#xD;
          -  Contra indication to dobutamine&#xD;
&#xD;
          -  Non ischaemic cardiomyopathy&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Manrique, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Yves Marie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Franken, MD</last_name>
    <role>Study Director</role>
    <affiliation>Free University of Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>B 1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sud-Francilien</name>
      <address>
        <city>Corbeil</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr 3;39(7):1151-8.</citation>
    <PMID>11923039</PMID>
  </reference>
  <reference>
    <citation>Everaert H, Vanhove C, Franken PR. Effects of low-dose dobutamine on left ventricular function in normal subjects as assessed by gated single-photon emission tomography myocardial perfusion studies. Eur J Nucl Med. 1999 Oct;26(10):1298-303.</citation>
    <PMID>10541828</PMID>
  </reference>
  <reference>
    <citation>Everaert H, Vanhove C, Franken PR. Effect of beta-blockade on low-dose dobutamine-induced changes in left ventricular function in healthy volunteers: assessment by gated SPET myocardial perfusion scintigraphy. Eur J Nucl Med. 2000 Apr;27(4):419-24.</citation>
    <PMID>10805115</PMID>
  </reference>
  <reference>
    <citation>Leoncini M, Sciagrà R, Maioli M, Bellandi F, Marcucci G, Sestini S, Chiocchini S, Dabizzi RP. Usefulness of dobutamine Tc-99m sestamibi-gated single-photon emission computed tomography for prediction of left ventricular ejection fraction outcome after coronary revascularization for ischemic cardiomyopathy. Am J Cardiol. 2002 Apr 1;89(7):817-21.</citation>
    <PMID>11909565</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Arteriosclerosis</keyword>
  <keyword>Heart Failure, Congestive</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Myocardial Revascularization</keyword>
  <keyword>Tomography, Emission-Computed, Single-Photon</keyword>
  <keyword>Dobutamine</keyword>
  <keyword>Myocardial Stunning</keyword>
  <keyword>Myocardial Hibernation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Myocardial Stunning</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

